Education & Discussion Guides
View these video modules on ERBB2/HER2 testing in NSCLC, strategies for overcoming barriers to broad-based biomarker testing, treatment options for patients with ERBB2/HER2-altered advanced/metastatic NSCLC, and workflows for optimal multidisciplinary care pathways. You can also find practical tools and patient cases featuring expert insights that you can apply in practice. Enhance the practice of precision medicine and improve care for your patients.
Do you want to bring this education to your team? Utilize the downloadable slide decks and the accompanying discussion guides listed below the videos. An additional video on adult learning principles and presentation tips is provided to help you develop and lead sessions with your team.
Dr. Bestvina describes biomarker testing and treatment in a patient case from her clinic
Tools and Resources
Use these tools and resources to enhance your processes, workflows, and clinical practice as a supplement to the education.
Clinical Tools, Workflows, and Processes
- Algorithm for biomarker testing when comprehensive testing is not possible
- Biomarker testing workflows
- Selecting cases for molecular tumor board review
- Tips for EBUS-TBNA
- Tissue collection workflows
- ACCC biomarker testing resources
- ACCC biomarker testing roadmap for NSCLC
- ACCC EHR integration tips to streamline testing
- ACCC report on biomarkers in NSCLC
- ACCC tips for integrating EHRs with reference labs
- CAP template for reporting biomarker testing results
Guidelines and Recommendations
- Acquiring tissue for comprehensive biomarker testing
- Consensus for ERBB2 testing in NSCLC
- Guidelines for biomarker testing of bronchoscopic biopsies
- IASLC consensus on molecular tumor boards
- Molecular testing paradigms in NSCLC
- NCCN guidelines for NSCLC
- Thoracic pathology statement on tissue stewardship
Articles of Interest
- Adopting NGS in oncology
- Best practices through the NSCLC treatment journey
- Biomarker testing and cost of care
- Communication between patients and HCPs in biomarker testing
- Communication practices for biomarker testing
- Emerging strategies in ERBB2-altered NSCLC
- Equitable biomarker testing in NSCLC
- ERBB2 evaluation for decision making
- IASLC survey on biomarker testing in NSCLC
- Improving diagnosis with NGS
- Insurance barriers to NGS testing in NSCLC
- Interpreting biomarker testing results
- Liquid biopsy approaches
- Molecular pathology perspective on biomarkers in NSCLC
- Molecular testing disparities in NSCLC
- Prevalence of ERBB2 alterations in NSCLC
- Strategies for EHR modernization
Prescribing Information
Patient Education & Resources
Patient education on biomarker testing
Patient education on treatment of lung cancer
Checklists for patients undergoing biomarker testing
Print and digital resources for patients with lung cancer and their caregivers
Comprehensive patient guide to NSCLC
Interested in participating in a digital quality improvement program? Think quality improvement is only possible in large, well-resourced hospital systems? The education and practical tools in this activity are also part of a scalable and customizable digital improvement program that was designed for efficient use in clinical practices of all sizes. Complete an assessment to identify how your processes align with pre-identified performance measures and then use the system to dynamically identify goals and create an action plan for improvement. Return 30+ days later and complete a reassessment. It’s that simple.
Enhance NSCLC biomarker testing with practical QI that you can apply now!
Begin Here
Hear from our expert faculty on why QI is essential for improving care of patients with advanced/metastatic NSCLC
You don’t realize what you’re doing right and what you’re doing wrong without measuring or assessing them. The process of going through a quality improvement program is that it makes you ask yourselves the right questions, some of which you might not have been thinking about, and seeing how you are doing with them. - Mark Yoder, MD
Each practice has its unique characteristics and has its own challenges in terms of early diagnosis or monitoring, or treatment of ILDs. This program allows clinicians to identity those unique areas that need to be improved so that clinical practice becomes more aligned with published guidelines. - Shervin Assassi, MD, MS